Torrent Pharma Derma Products

by

Find Torrent Pharmaceuticals products price online from India. Buy Medicines manufactured. Dermanex Mometasone Furoate 0.1% Cream DEFAULT86. The company launched two biosimilars in India, to increase focus on specialty portfolio. It also acquired and amalgamated a US FDA approved derma products manufacturing facility of Zyg Pharma at Pithampur in Indore during the last four years.

Ahmedabad based Torrent Pharma enters New Year 2016 by announcing the launch of biosimilar Adalimumab in India under the brand name ‘Adfrar’. Adalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis.

Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD). Torrent’s brand ‘Adfrar’ will be the second biosimilar Adalimumab in the world. Autoimmune disorders are growing ailments and Monoclonal Antibodies (MAb’s) are becoming mainstay of treatment, therefore launch of ‘Adfrar’ is a significant step towards fortifying its presence in MAb market. Biosimilar Rituximab - ‘Toritz RA’ is already launched in Rheumatology segment and now with launch of biosimilar Adalimumab - ‘Adfrar’, Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality. ‘Adfrar’ will be available as Pre Filled Syringe of 40mg. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India, for which three separate super specialty task force have been introduced.

Devid siberi iskusstvo egoizma chitatj. Around 100 highly trained professionals are employed in these Greenfield divisions. This super speciality team, besides promoting biosimilar Adalimumab – ‘Adfrar IB’ to Gastroenterologists, will also cater to the advanced therapy needs in Hepatology. Torrent has launched new generation Hep C Antiviral Sofosbuvir – ‘Sofocruz’, a combination of Sofosbuvir + Ledipasvir - ‘Sofocruz LP’ and Daclatasvir – ‘Daclacruz’. Moreover, the company has also launched Hep B Antiviral Tenofovir – ‘Tenocruz’.

Torrent is already marketing biosimilar Rituximab ‘Toritz’ in Oncology segment, while a super specialty division for Nephrology launched in 2014 is marketing biosimilar Darbepoetin alpha - ‘Darbatitor’. Regarding the expected business from these biosimilars, Executive Director - Marketing of Torrent Pharma Mr.Ruchir Modi said that since inception, its focus was never with business intent alone, rather it is a by product. Its purpose has always been to launch specialty niche products to address unmet medical needs arising from major life threatening diseases and reach out to maximum number of patients to offer cost effective treatment with latest quality drugs. He further added that with introduction of these new super specialty divisions, Torrent Pharma now covers most of the specialties and in near future plans to enter Urology and Opthalmology segments to cover the therapy gaps with strategic fit products. Torrent is amongst the top 20 companies in India with over 23% growth on MAT Nov’15 basis and currently ranked 16th. About Torrent: Torrent Pharma, with annual revenues of almost Rs.

4700 Crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset). Torrent has a full equipped Research Centre, employing almost 800 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets.

The Company's manufacturing plants located at Indrad, Baddi, Sikkim and Dahej have facilities to produce Formulations and Bulk drugs. The recently acquired Pithampur plant in Madhya Pradesh has capacity to produce derma products. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.